ArticleCureus2025
A Rare Case of Myelofibrosis Progressing to BCR-ABL1-Positive Chronic Myeloid Leukemia With Discordant Molecular Testing.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelofibrosis is a chronic myeloproliferative neoplasm (CMN) characterized by bone marrow fibrosis, splenomegaly, cytopenias, or cytoses, and a propensity for transformation into acute myeloid leukemia (AML). Transformation of myelofibrosis into chronic myeloid leukemia (CML), however, is extremely rare and poorly understood. CML is typically defined by the presence of the BCR-ABL1 fusion gene, a product of the Philadelphia chromosome t(9;22)(q34;q11), which leads to constitutive activation of a tyrosine kinase that drives leukemogenesis. This molecular abnormality is considered pathognomonic for CML and is routinely identified through techniques such as fluorescence in situ hybridization (FISH) and reverse transcriptase-polymerase chain reaction (RT-PCR). While the transformation from myelofibrosis to CML is unusual, this case report illustrates an unusual transformation of myelofibrosis to CML, marked by the emergence of a BCR-ABL1-positive clone detectable by fluorescence in situ hybridization (FISH) but not by polymerase chain reaction (PCR). It underscores the importance of using multiple complementary molecular diagnostic techniques when evaluating disease progression in myeloproliferative neoplasms. Early recognition of such atypical transformations is essential, as it can open the door to targeted therapies that may significantly alter the patient's prognosis and clinical trajectory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.